SuperworthNeuronetics profit margin STIM
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- −19.6%
- Operating margin, 12 months
- −14.7%
- Net margin on a year earlier
- +24.3 pts
- Peer median
- 6.9%
Over the twelve months to Jun 30, 2026, Neuronetics kept −19.6% of its revenue as net profit, with an operating margin of −14.7% and a gross margin of 49.1%.
Five years earlier its net margin was −41.2%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −26.1% | −21.1% | 48.5% |
| FY2024 | −58.4% | −46.2% | 72.3% |
| FY2023 | −42.3% | −42.8% | 72.5% |
| FY2022 | −57.0% | −53.8% | 76.3% |
| FY2021 | −56.4% | −49.8% | 78.9% |
| FY2020 | −55.7% | −45.3% | 76.5% |
| FY2019 | −46.4% | −43.0% | 75.4% |
| FY2018 | −45.7% | −37.6% | 76.4% |
| FY2017 | −39.7% | −33.7% | 76.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −19.6% | +24.3 pts | −14.7% | |
| Q1 FY26 | −24.5% | +29.8 pts | −19.4% | |
| Q4 FY25 | −26.1% | +32.2 pts | −21.1% | |
| Q3 FY25 | −34.3% | +15.8 pts | −29.2% | |
| Q2 FY25 | −43.9% | +1.1 pts | −34.4% | |
| Q1 FY25 | −54.2% | −16.6 pts | −43.3% | |
| Q4 FY24 | −58.4% | −16.1 pts | −46.2% | |
| Q3 FY24 | −50.1% | −2.3 pts | −37.8% | |
| Q2 FY24 | −45.1% | +1.1 pts | −39.8% | |
| Q1 FY24 | −37.6% | +17.7 pts | −37.6% | |
| Q4 FY23 | −42.3% | +14.7 pts | −42.8% | |
| Q3 FY23 | −47.8% | +11.0 pts | −48.9% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Neuronetics' size, closest first, today.
| Company | Profit margin |
|---|---|
| STIMNeuronetics | −19.6% |
| PDEXPro DEX | 17.6% |
| UTMDUtah Medical Products | 29.0% |
| KEQUKewaunee Scientific | 3.0% |
| INFUInfuSystem | 6.0% |
| EMBCEmbecta | 8.6% |
| APTAlpha Pro Tech | 6.8% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| NEPHNephros | 8.4% |
| MOVMovado | 6.0% |
| Peer median | 6.9% |
Where Neuronetics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Neuronetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.